GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Phase 1

Terminated

Conditions: Severe Renal Impairment

Interventions: Drug: RANEXA

First Posted Date: 2012-08-30

Last Posted Date: 2012-12-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 4

Registration Number: NCT01675973

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

Phase 2

Terminated

Conditions: Liver Fibrosis Due to NASH

Interventions: Biological: Placebo
Biological: SIM

First Posted Date: 2012-08-27

Last Posted Date: 2019-03-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 259

Registration Number: NCT01672879

Locations: 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
Southern California Liver Centers, Coronado, California, United States
🇺🇸
University of California, San Diego (UCSD), San Diego, California, United States

and more 56 locations

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Liver Fibrosis Due to NASH

Interventions: Biological: SIM
Biological: Placebo

First Posted Date: 2012-08-27

Last Posted Date: 2019-03-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 222

Registration Number: NCT01672866

Locations: 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 65 locations

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

Phase 2

Completed

Conditions: Primary Sclerosing Cholangitis (PSC)

Interventions: Biological: Simtuzumab
Biological: Placebo

First Posted Date: 2012-08-27

Last Posted Date: 2019-10-22

Lead Sponsor: Gilead Sciences

Target Recruit Count: 235

Registration Number: NCT01672853

Locations: 🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸
Southern California Liver Center, Chula Vista, California, United States
🇺🇸
Southern California Liver Centers, Coronado, California, United States

and more 72 locations

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

Phase 1

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: GS-7340
Drug: Tenofovir disoproxil fumarate

First Posted Date: 2012-08-24

Last Posted Date: 2018-10-23

Lead Sponsor: Gilead Sciences

Target Recruit Count: 51

Registration Number: NCT01671787

Locations: 🇬🇧
Institute of Liver Studies, King's College Hospital, London, United Kingdom
🇬🇧
Grahame Hayton Unit, London, United Kingdom
🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia

and more 16 locations

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Phase 3

Completed

Conditions: Human Immunodeficiency Virus
Hepatitis C

Interventions: Drug: SOF
Drug: RBV

First Posted Date: 2012-08-17

Last Posted Date: 2014-11-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 224

Registration Number: NCT01667731

Phase I Study of Milatuzumab for Graft Versus Host Disease

Phase 1

Terminated

Conditions: GVHD (Acute or Chronic)
Multiple Myeloma (MM)
Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
Myelodysplastic Syndrome
Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Chronic Myelogenous Leukemia (CML)

Interventions: Drug: milatuzumab

First Posted Date: 2012-08-13

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 12

Registration Number: NCT01663766

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Phase 2

Withdrawn

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: GS-1101

First Posted Date: 2012-08-07

Last Posted Date: 2012-09-07

Lead Sponsor: Gilead Sciences

Registration Number: NCT01659047

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Phase 1

Completed

Conditions: Non Hodgkins Lymphoma
Chronic Lymphocytic Leukaemia

Interventions: Drug: Tirabrutinib

First Posted Date: 2012-08-07

Last Posted Date: 2021-03-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 90

Registration Number: NCT01659255

Locations: 🇫🇷
CHU St Eloi, Montpellier, France
🇫🇷
CHRU - Hopital Claude HURIEZ, Lille, France
🇫🇷
Centre hospitalier Lyon Sud, Lyon, France

and more 3 locations

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Phase 3

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Idelalisib
Drug: Ofatumumab

First Posted Date: 2012-08-07

Last Posted Date: 2019-08-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 261

Registration Number: NCT01659021

Locations: 🇺🇸
Saint Mary's Regional Cancer Center, Grand Junction, Colorado, United States
🇺🇸
Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 75 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy